To assess the possible contribution of the circulatory and cardiac renin-angiotensin system (RAS) to the cardiac hypertrophy induced by a beta-agonist, the present study evaluated the effects of isoproterenol, alone or combined with an angiotensin I-converting enzyme inhibitor or AT(1) receptor blocker, on plasma and LV renin activity, ANG I, and ANG II, as well as left ventricular (LV) and rig...

CLINICAL PHARMACOLOGY Mechanism of Action: Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result prim...

anastrozole for 10 weeks; after 4 weeks they received quinapril for 28 days; blood samples were taken at the same time as group A. Blood pressure was measured at the time of entry, before starting quinapril and twice a day during the 4 weeks of treatment with ACE inhibitor. Primary assessment was the steady-state plasma anastrozole concentrations following once-daily anastrozole alone or anastr...

Angiotensin-converting enzyme (ACE) inhibitors appear to correct many of the abnormalities associated with the vascular dysfunction found in diabetic patients. In this respect, quinapril is a unique ACE inhibitor with multiple protective effects. The present study was carried out to investigate the effect of intraperitoneal administration of quinapril on the aortic reactivity of streptozotocin ...

Bradykinin is a nonapeptide that contributes to the cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitors. During ACE inhibition, an increased proportion of bradykinin is degraded through non-ACE pathways. Studies in animals suggest that aminopeptidase P (EC 3.4.11.9) may contribute to the metabolism of bradykinin. The purpose of the present study was to determine the contr...

INTRODUCTION The angiotensin-converting enzyme (ACE) DD-genotype is associated with increased plasma and myocardial ACE-activity. The influence of the ACE insertion/deletion (I/D) polymorphism on the effects of ACE-inhibition on vascular responses has not been previously described. MATERIALS AND METHODS In the randomised, double-blind QUinapril On Vascular ACE and Determinants of Ischemia Stu...

Clinical studies indicate that the angiotensin-converting enzyme inhibitor quinapril is an effective antihypertensive agent when administered once daily. At the end of a 4-week, double-blind crossover trial comparing quinapril and placebo, patients were admitted for a hemodynamic profile study 12 hours after taking the previous dose. A final 20 mg dose of quinapril had no additional effect on b...

The pharmacokinetics of quinapril, a novel angiotensin converting enzyme (ACE) inhibitor, and its active metabolite, quinaprilat, were determined following a single 20-mg oral dose of quinapril in six patients with chronic renal failure maintained on continuous ambulatory peritoneal dialysis (CAPD). Overall, quinapril was well tolerated by these CAPD patients, with mild and transient side effec...

Angiotensin converting enzyme (ACE) inhibitors are important therapeutic agents for treating patients with hypertension and cardiovascular diseases. Although most ACE inhibitors are cleared by the kidney via glomerular filtration and tubular secretion, little is known about their reabsorption potential. In particular, it is believed that while certain ACE inhibitors are transported by the intes...

Chapter 4 50 The present study aimed to examine the effects of long-term treatment with the angiotensin-converting-enzyme-inhibitor quinapril on markers of inflammation in patients requiring coronary artery bypass grafting. We performed a subgroup analysis of a prospective, placebo-controlled , randomized, multi-center study evaluating quinapril 40 mg. once daily in patients scheduled to underg...